Showing results (61-70 of 170) with videos related to

Sort By:
Pageof 17
Blood|October 1, 2008
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Erik A Nelson, Sarah R Walker, Alicia Kepich, et al.
British Journal of Haematology|May 11, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patientsNancy Levin, Andrew Spencer, Simon J Harrison, et al.
Cancer Management and Research|December 29, 2010
Bortezomib in the management of multiple myelomaJacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al.
British Journal of Haematology|January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
Oncotarget|October 15, 2017
Melflufen - a peptidase-potentiated alkylating agent in clinical trialsMalin Wickström, Peter Nygren, Rolf Larsson, et al.
British Journal of Haematology|July 8, 2011
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settingsPaul G Richardson, Jacob Laubach, Constantine S Mitsiades, et al.
Blood|October 24, 2002
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Teru Hideshima, Constantine Mitsiades, Masaharu Akiyama, et al.
Seminars in Hematology|April 25, 2009
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomibConstantine S Mitsiades, Teru Hideshima, Dharminder Chauhan, et al.
Pageof 17